Clinical Trial

IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure

Study acronym: IRONHEART
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to observe the effect of intravenous ferric derisomaltose in participants with non-ischaemic heart failure (LVEF\<40%), iron deficiency (TSATS\<20%) and established on heart failure therapy including Sodium-glucose cotransporter 2 inhibitors (SGLT2i). Participants will undergo baseline laboratory blood tests, cardiac magnetic resonance imaging (cMRI), six-minute walk test, musculoskeletal function test and Kansas City Cardiomyopathy Questionnaire (KCCQ). These investigations will be repeated at 24 hours and 30 days after the administration of intravenous ferric derisomaltose.
Trial Details
NCT Number NCT06542822
Lead Sponsor University Hospital Southampton NHS Foundation Trust
Collaborators: Portsmouth Hospitals NHS Trust
Conditions Heart Failure, Iron Deficiencies
Enrollment 16 participants
Start Date 2024-04-15
Primary Completion 2026-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-07